Status:
RECRUITING
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Lead Sponsor:
Kyowa Kirin, Inc.
Conditions:
Leukemia/Lymphoma
Cutaneous T Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted begin...
Detailed Description
This is an observational, retrospective and prospective study where subjects who have received mogamulizumab either within one year before or within 18 months after transplantation will be followed fo...
Eligibility Criteria
Inclusion
- Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Adults ≥18 years of age with either CTCL or ATLL;
- AlloHCT performed from January 2012 onward.
Exclusion
- • Patients without consent for research.
Key Trial Info
Start Date :
September 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2030
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04014374
Start Date
September 10 2019
End Date
February 1 2030
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIBMTR
Milwaukee, Wisconsin, United States, 53226